September 20, 2016
Cambridge, MA

The First Therapy for Duchenne Muscular Dystrophy

Solid Biosciences congratulates Sarepta on the U.S. approval of EXONDYS 51™ (eteplirsen), the first therapy for Duchenne muscular dystrophy. It would not have been possible without the tireless work and commitment of the team at Sarepta, the patient community, the FDA and all those driven to make an approved therapy a reality.

We at Solid hope this event marks the first of many approvals for future therapies that will benefit all patients with this devastating disease. Our mission is to discover and develop treatments that address the full spectrum of Duchenne muscular dystrophy – from its underlying cause to the secondary disorders that result from the disease.

Related news


Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President
Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities


We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.


- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway

- Conference Call Scheduled for Today at 8:30 A.M. ET


- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -

- Company Continues to Advance Gene Therapy Portfolio -

Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -


Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.


Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.


Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day


Phase I/II adaptive clinical trial to evaluate safety and efficacy in ambulatory and non-ambulatory children and adolescents.


More information about Solid?

Please subscribe to receive our latest news